ContraVir Pharmaceuticals Inc Share Price Nasdaq
Equities
US21234W2026
Biotechnology & Medical Research
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 7.99M 667M |
---|---|---|---|---|---|
Net income 2024 * | -51M -4.25B | Net income 2025 * | -76M -6.34B | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-0.14
x | P/E ratio 2025 * |
-
| Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.69% |
Managers | Title | Age | Since |
---|---|---|---|
John Cavan
CEO | Chief Executive Officer | 65 | 01/16/01 |
Daren Ure
CTO | Chief Tech/Sci/R&D Officer | - | 03/19/03 |
Stephen Kilmer
IRC | Investor Relations Contact | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
John Brancaccio
CHM | Chairman | 76 | 15/13/15 |
Timothy Block
BRD | Director/Board Member | 69 | 26/13/26 |
Kaouthar Lbiati
BRD | Director/Board Member | 45 | 27/22/27 |
1st Jan change | Capi. | |
---|---|---|
+8.96% | 105B | |
-1.43% | 104B | |
+4.40% | 22.94B | |
-12.15% | 22.34B | |
-4.36% | 19.25B | |
-39.98% | 17.08B | |
-10.04% | 16.96B | |
+6.79% | 14.16B | |
+38.61% | 12.63B |